Senior Advisor Subject Matter Expert (SME) with Pharmaceutical Development and Pain Expertise for the NINDS

Ce que l'acheteur demande

COMBINED SYNOPSIS / SOLICITATION (COMPETITIVE) Title: Senior Advisor Subject Matter Expert (SME) with Pharmaceutical Development and Pain Expertise for the NINDS Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative for the Pain Therapeutics Development Program (PTDP) (i) This is a combined synopsis/solicitation for commercial products or commercial services prepared in accordance with RFO Part 12. This announcement constitutes the only solicitation. Offers are being requested and a separate written solicitation will not be issued. The solicitation number is 7571PSQ00007 issued as a Request for Quote for a Senior Advisor to act as a Subject Matter Expert (SME) with Pharmaceutical Development and Pain Expertise. The Government reserves the right to make one award, multiple awards, or no awards as a result of this solicitation. This acquisition is set-aside for small business concerns. This solicitation incorporates provisions and clauses by reference. The full text of provisions and clauses may be accessed electronically at www.acquisition.gov. The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (ii) This requirement is for the following services: NINDS is seeking to procure a highly experienced executive-level, drug discovery and development Senior Advisor 2 with extensive expertise in drug discovery and development, in support of the NIH HEAL Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. (iii) Description of requirement: The NIH is seeking to procure a highly experienced executive-level Senior Advisor 2, drug discovery and development subject matter expert with experience in the area of Pharmacology and Pain to provide feedback to the NIH program leadership and technical guidance on drug discovery and development projects within the NINDS HEAL portfolio. The Contractor will serve as a member of the HEAL External Oversight Committee, which will provide strategic guidance on HEAL projects and on occasion other NIH drug discovery and development programs. See Attachment #1 - Statement of Work (SOW) for more information. (iv) The Government anticipates award of a Fixed Price purchase order for this acquisition, and the anticipated base period of performance is: Base: 11/5/2026 – 11/4/2027 Option Year 1: 11/5/2027 – 11/4/2028 Option Year 2: 11/5/2028 – 11/4/2029 (v) The provisions at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at this address: https://www.acquisition.gov/far-overhaul https://www.hhs.gov/contract-policies-regulations/hhsar-overhaul (End of provision) a) The following FAR provisions are required by FAR 12.2025(a), and incorporated by reference: • FAR 52.212-1 (Nov 2025) (RFO Deviation), Instructions to Offerors-Commercial Products and Commercial Services. b) The following FAR provisions are required as applicable to this requirement and incorporated by reference: • See Attachment 2 for (Table # 12-2) under FAR 12.205 (a)(3). c) The following HHSAR provisions are applicable to this requirement and incorporated by reference (available upon request): • HHSAR 352.239.78 – Information and Communication Technology Accessibility Notice (FEB 2024) (Deviation) (vi) The clauses at FAR 52.252-2,…

Langue de cet avis : English. Le titre et la description sont affichés tels que publiés par l'acheteur.